Quick Answer
ONCOLYTICS BIOTECH INC reported R&D Expense of $13.31 million for fiscal year 2025.
ONCOLYTICS BIOTECH INC R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $13.31M | -13.8% |
| 2024 | $15.44M | -12.8% |
| 2023 | $17.71M | +14.8% |
| 2022 | $15.43M | +19.4% |
| 2021 | $12.92M | -0.2% |
| 2020 | $12.95M | +19.7% |
| 2019 | $10.82M | +7.9% |
| 2018 | $10.03M | +6.8% |
| 2017 | $9.39M | -3.9% |
| 2016 | $9.77M | +13.6% |
| 2015 | $8.60M | — |
- ONCOLYTICS BIOTECH INC showed a decrease of -13.8% in R&D Expense compared to the prior fiscal year.
- Over the 2015–2025 period, ONCOLYTICS BIOTECH INC’s r&d expense has grown by 54.8% (from $8.60 million to $13.31 million).
- The most recent figure is from ONCOLYTICS BIOTECH INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: